Deutsche Bank AG Acquires 12,060 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Deutsche Bank AG increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 169,323 shares of the company's stock after acquiring an additional 12,060 shares during the period. Deutsche Bank AG owned about 0.35% of Mirum Pharmaceuticals worth $7,002,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of MIRM. Jones Financial Companies Lllp lifted its stake in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $69,000. AlphaQuest LLC lifted its stake in shares of Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after acquiring an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in shares of Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after acquiring an additional 312 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $189,000.

Mirum Pharmaceuticals Stock Down 0.1%

Shares of MIRM stock traded down $0.05 during midday trading on Friday, reaching $44.00. 164,520 shares of the stock were exchanged, compared to its average volume of 522,623. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.83 and a 1 year high of $54.23. The company's 50 day moving average is $42.95 and its two-hundred day moving average is $44.59. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.18 billion, a PE ratio of -21.78 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. During the same quarter in the prior year, the business earned ($0.54) EPS. The business's revenue for the quarter was up 61.2% on a year-over-year basis. On average, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent research reports. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Raymond James restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities boosted their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday, May 9th. Finally, HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $60.73.

Insiders Place Their Bets

In other news, Director Patrick J. Heron bought 1,335 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the acquisition, the director now owns 163,643 shares of the company's stock, valued at approximately $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jolanda Howe sold 57,606 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now owns 4,841 shares in the company, valued at $214,698.35. This trade represents a 92.25% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 92,764 shares of company stock worth $4,109,161. Company insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.